Zymeworks (NYSE: ZYME)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.670 | -1.190 | 0.4800 | ||||
REV | 3.470M | 1.916M | -1.554M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Zymeworks (NYSE: ZYME) through any online brokerage.
Other companies in Zymeworks’s space includes: Humacyte (NASDAQ:HUMA), bluebird bio (NASDAQ:BLUE), Precigen (NASDAQ:PGEN), Burning Rock Biotech (NASDAQ:BNR) and Mesoblast (NASDAQ:MESO).
The latest price target for Zymeworks (NYSE: ZYME) was reported by SVB Leerink on Friday, May 27, 2022. The analyst firm set a price target for 19.00 expecting ZYME to rise to within 12 months (a possible 233.33% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Zymeworks (NYSE: ZYME) is $5.7 last updated July 6, 2022, 7:59 PM UTC.
There are no upcoming dividends for Zymeworks.
Zymeworks’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for Zymeworks.
Zymeworks is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.